Mattsson L, Gutierrez R A, Dawson G J, Lesniewski R R, Mushahwar L K, Weiland O
Dept. of Infectious Diseases, Karolinska Institute, Roslagstull Hospital, Stockholm, Sweden.
Scand J Gastroenterol. 1991 Dec;26(12):1257-62. doi: 10.3109/00365529108998622.
Eight of 13 Swedish patients (62%), studied prospectively, who developed posttransfusion non-A, non-B hepatitis (PT-NANBH) had earlier been found to seroconvert for antibodies to hepatitis C virus (anti-HCV) c100-3 in the first-generation anti-HCV enzyme-linked immunosorbent assay 1-18 (mean, 8) weeks after onset of hepatitis. By using a second-generation test utilizing antigens encoded by the core NS3 and NS4 region of HCV, a further four patients non-reactive to c100-3 (NS4) were found to seroconvert. Thus 12 of 13 (92%) Swedish patients with PT-NANBH were shown to have HCV infection. In addition, the serologic reactivity for several individual synthetic peptides and/or recombinant HCV proteins was studied in seven anti-HCV c100-3 seroconverts studied long-term after onset of acute PT-HCV infection. No special patterns were found that could differentiate patients who recovered from those who developed chronic HCV infection. It was concluded that the addition of new recombinant antigens derived from the core and NS3 region to c100-3 (NS4) both improved the sensitivity of the anti-HCV test and shortened the window phase to seroconversion.
在一项前瞻性研究中，13例发生输血后非甲非乙型肝炎（PT-NANBH）的瑞典患者中有8例（62%），在肝炎发病后1至18周（平均8周），于第一代抗丙型肝炎病毒（HCV）酶联免疫吸附试验中被发现针对HCV c100-3抗体发生血清转化。通过使用一种利用HCV核心NS3和NS4区域编码抗原的第二代检测方法，又发现另外4例对c100-3（NS4）无反应的患者发生血清转化。因此，13例瑞典PT-NANBH患者中有12例（92%）被证实感染HCV。此外，在7例急性PT-HCV感染发病后长期进行研究的抗-HCV c100-3血清转化者中，对几种单个合成肽和/或重组HCV蛋白的血清学反应性进行了研究。未发现可区分康复患者与发生慢性HCV感染患者的特殊模式。得出的结论是，在c100-3（NS4）中添加源自核心和NS3区域的新重组抗原，既提高了抗-HCV检测的敏感性，又缩短了血清转化的窗口期。
